Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14183637 | 0.97 | MIF (0.54) | MEN1CYP1A2CYP2C19KMT2AMIF | |
| SCHEMBL6042101 | 0.89 | MEN1 (0.51) | MEN1CYP1A2CYP2C19KMT2AMIF | |
| SCHEMBL28564102 | 0.84 | NPC1 (0.65) | MEN1CYP1A2CYP2C19KMT2AMIF | |
| SCHEMBL4951608 | 0.83 | LMNA (0.53) | MIFLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL3326726 | 0.83 | LMNA (0.53) | MIFLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL14183685 | 0.83 | NPC1 (0.52) | MIFNPC1RAB9A | |
| SCHEMBL5994929 | 0.83 | POLB (0.56) | CYP1A2CYP2C19MIFNPC1POLB | |
| SCHEMBL3326724 | 0.83 | LMNA (0.53) | MIFLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL5994924 | 0.83 | POLB (0.56) | CYP1A2CYP2C19MIFNPC1POLB | |
| SCHEMBL15009301 | 0.82 | LMNA (0.52) | MEN1CYP1A2CYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998390-B2 | Oxolide antibacterials | ABBVIE INC. | 2006-02-14 | — | — | US | claimed |
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | claimed |
| US-6998390-B2 | Oxolide antibacterials | ABBVIE INC. | 2006-02-14 | — | — | US | disclosed |
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1499326-A1 | OXOLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-0907625-A4 | FLUOROUS REACTION AND SEPARATION SYSTEMS | UNIV PITTSBURGH (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-0907625-A1 | FLUOROUS REACTION AND SEPARATION SYSTEMS | UNIVERSITY OF PITTSBURGH (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5859247-A | Fluorous reaction and separation systems | UNIVERSITY OF PITTSBURGH (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998000376-A1 | FLUOROUS REACTION AND SEPARATION SYSTEMS | UNIVERSITY OF PITTSBURGH (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| WO-1991016316-A1 | PROCESS FOR PREPARING ISOXAZOLINES | BP CHEMICALS LIMITED (GB) | 1991-10-31 | — | — | WO | disclosed |
| EP-0453189-A1 | Process for preparing isoxazolines | von Oppolzer, Wolfgang Wilhelm R.E.J. (CH) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014688-A1 | Oxolide antibacterials | OGFOD1, PGLS, OXER1 | MEN1 1879/4885CYP1A2 236/4885CYP2C19 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.